7 Result(s)
-
Article
Recombinant human interleukin-11 for treatment of chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer
To evaluate the efficacy and safety of recombinant human interleukin-11 (rhlL-11) for the chemotherapy-induced thrombocytopenia in patients with gastrointestintal cancer.
-
Article
Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study
To estimate the burden of human papillomavirus (HPV) infection among sexually active women in China.
-
Article
Open AccessMedical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002–2011)
Esophageal cancer is associated with substantial disease burden in China, and data on the economic burden are fundamental for setting priorities in cancer interventions. The medical expenditure for the diagnos...
-
Article
HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer
Rate-limiting enzyme 3b-hydroxysteroid dehydrogenase type 1 (3βHSD1) encoded by HSD3B1 catalyzes the transition of dehydroepiandrosterone (DHEA) to dihydrotestosterone (DHT). The HSD3B1 (1245C) variant renders...
-
Article
Open AccessTargeting HNRNPU to overcome cisplatin resistance in bladder cancer
The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance. The genes th...
-
Article
Open AccessACE2-independent infection of T lymphocytes by SARS-CoV-2
SARS-CoV-2 induced marked lymphopenia in severe patients with COVID-19. However, whether lymphocytes are targets of viral infection is yet to be determined, although SARS-CoV-2 RNA or antigen has been identifi...
-
Article
A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study
Osimertinib is the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with T790M mutation after the failure of first-/second-generation epidermal growth factor receptor tyrosine kinase...
